Controversial and unresolved issues in the classification of surgically implanted biological heart valve prostheses (problem lecture)

One of the significant areas of cardiac surgery is the replacement of damaged or faulty heart valves. Biological heart valve prostheses created from biological tissues represent a significant achievement in this area, providing effective treatment and improving the quality of life of patients.

Aim: To analyze and discuss unresolved issues in the classification of surgically implanted biological heart valve prostheses. Various approaches to the classification of biological heart valve prostheses are presented, including from the standpoint of their historicity. Particular attention is paid to the prospects for the development of combined technologies in the creation of heart valve prostheses. Thus, the rapid development of biological and engineering technologies makes significant adjustments to the very concept of “biological heart valve prosthesis”. A transformation in the production of these medical devices is expected, which is already associated with the development and implementation of bioengineering technologies in clinical practice, which may lead to the abandonment of existing methods of production and use of biopolymers (collection from animals and fixation /sterilization /storage in glutaraldehyde or a similar agent). It is obvious that in the near future, synthetic, combined bioprostheses and valves created on the basis of promising tissue engineering technologies will appear. Innovative tissue and cell prostheses already include structures created from patient cells or using bioprinting. In general, these technologies are aimed at creating prostheses that can have an ideal match to the patient's anatomy and minimize the risk of rejection. Such valves are likely to be stronger, less likely to cause complications and easier to implant.

1. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 2005;5:685–694. https://doi.org/10.1016/S1473-3099(05)70267-X

2. Pezzella A.T. International cardiac surgery: a global perspective. Semin. Thorac. Cardiovasc. Surg. 2002;14:298–320. https://doi.org/10.1053/stcs.2002.0140298

3. Zilla P., Brink J., Human P., Bezuidenhout D. Prosthetic heart valves: catering for the few. Biomaterials. 2008;29(4):385–406. https://doi.org/10.1016/j.biomaterials.2007.09.033

4. Russo M., Taramasso M., Guidotti A., Pozzoli A., Von Segesser L.K., Nietlispach F. et al. The evolution of surgical valves. Cardiovascular medicine. 2017;20(12): 285–292. http://doi.org/10.4414/cvm.2017.00532

5. Angell W.W., Angell J.D., Sywak A. The tissue valve as a superior cardiac valve replacement. Surgery. 1977;82(6):875–887. URL: https://pubmed.ncbi.nlm.nih.gov/401529/(07.04.2025).

6. Leon M., Smith C., Mack M., Miller D.C., Moses J.W., Svensson L.G. et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 2010;363:1597–1607. https://doi.org/10.1056/nejmoa1008232

7. Mack M., Leon M., Thourani V., Makkar R., Kodali S.K., Russo M. et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N. Engl. J. Med. 2019;380:1695–1705. https://doi.org/10.1056/NEJMoa1814052

8. Binet J.P., Duran C.G., Carpentier A. Heterologous aortic valve transplantation. The Lancet. 1965;2(7425):1275. https://doi.org/10.1016/s0140-6736(65)92287-7

9. Onishchenko P.S., Klyshnikov K.Yu., Ovcharenko E.A. Optimization of the biological heart valve prosthesis “Uniline”: new tools for improving function. Russian Journal of Biomechanics. 2024;28(1):10–22. (In Russ.). URL: https://sciup.org/optimizacija-biologicheskogo-proteza-klapana-serdca-junilajnnovye-instrumenty-146282930 (07.04.2025).

10. Ozaki S., Kawase I., Yamashita H., Uchida S., Nozawa Y., Matsuyama T. et al Aortic valve reconstruction using self-developed aortic valve plasty system in aortic valve disease. Interact. Cardiovasc. Thorac. Surg. 2011;12(4):550–553. https://doi.org/10.1510/icvts.2010.253682

11. Vilela Batista R.J., Dobrianskij A., Comazzi M. Jr., Lessa Neto L.T., Rocha G. Sartori F. et al. Clinical experience with stentless pericardial aortic monopatch for aortic valve replacement. J. Thorac. Cardiovasc. Surg. 1987;93(1):19–26. https://pubmed.ncbi.nlm.nih.gov/3796028/

12. Ross D.N. Homograft replacement of the aortic valve. Lancet. 1962;2(7254):487. https://doi.org/10.1016/s0140-6736(62)90345-8.

13. Barrat`-Boyes B. Homograft aortic valve replacement in aortic incompetence and stenosis. Thorax. 1964;19(2):131–150. https://doi.org/10.1136/thx.19.2.131

14. Heimbecker R.O., Baird R.J., Lajos R.Z., Varga A.T., Greenwood W.F. Homograft replacement of the human mitral valve: a preliminary report. Can. Med. Assoc. J. 1962;86(18):805–809. PMID: 13906027.

15. Malinovsky N.N., Konstantinov B.A., Dzemeshkevich S.L. Biological prostheses of heart valves. Moscow: Medicine; 1988:256. (In Russ.). ISBN 5-225-00165-3.

16. Kumar D. Evolution of bioprosthetic valves, where we are heading. International Journal of Cardiovascular and Thoracic Surgery. 2023;9(5):63–66. https://doi.org/10.11648/j.ijcts.20230905.11

17. Bartek I.T., Holden M.P., Ionescu M.I. Frame-mounted tissue heart valves: technique of construction. Thorax. 1974;29(1):51. https://doi.org/10.1136/thx.29.1.51

18. Carpentier A., Blondeau P., Laurens B., Hay A., Laurent D., Dubost C. Mitral and tricuspid valve replacement with frame-mounted aortic heterografts. J. Thorac. Cardiovasc. Surg. 1968;56(3):388–394. PMID: 5692507.

19. Franzese I., Francica A., Tropea I., Tonelli F., San Biagio L., Luciani G.B. et al. Edwards INSPIRIS RESILIA valve for aortic valve replacement achieves acute reverse remodelling of the left ventricle and maintains excellent hemodynamic profile after 1 year in young adults. Structural heart. 2020;4(S1):106. http://dx.doi.org/10.1080/24748706.2020.1717231

20. Murashita T., Okada Y., Kanemitsu H., Fukunaga N., Konishi Y., Nakamura K. et al. Efficacy of stentless aortic bioprosthesis implantation for aortic stenosis with small aortic annulus. Thorac. Cardiovasc. Surg. 2015;63(6):446–451. https://doi.org/10.1055/s-0034-1389106

21. Doss M., Risteski P., Wood J.P., Wimmer-Greinecker G., Moritz A. In-vivo evaluation of the BioPhysio™ valve prosthesis in the aortic position. Journal of Heart Valve Disease. 2008;17(1):105–109. PMID: 18365577.

22. Evtushenko A.V., Lebedev D.I., Barbarash L.S. Sizova I.N., Lebedev D.I., Duvanov M.K. et al. Immediate results of the use of the biological semiframe prosthesis “Tiara” and the frame biological prosthesis “UniLine”: propensity score matching analysis. Complex issues of cardiovascular diseases. 2022;11(4S):75–87. (In Russ.). https://doi.org/10.17802/23061278-2022-11-4S-75-87

23. Астапов Д.А. Биологические протезы при хирургическом лечении клапанных пороков сердца у взрослых больных. Дис. … д-ра мед. наук: 14.01.26. Новосибирск; 2012:337; 24 ил. URL: https://rusneb.ru/catalog/000199_000009_005092314/ (03.04.2025).

24. Astapov D.A. Biological prostheses in surgical treatment of valvular heart defects in adult patients. Dissertation for Doctor of Medical Sciences: 14.01.26. Novosibirsk; 2012:361 (In Russ.). URL: https://rusneb.ru/catalog/000199_000009_005092314/ (03.04.2025).

25. Buch W.S., Kosek J.C., Angell W.W. Shumway S.E. Deterioration of formalin-treated aortic valve heterografts. J. Thorac. Cardiovasc. Surg. 1970;60(5):673–682. PMID: 5475219.

26. Carpentier A., Lemaigre G., Robert L., Carpentier S., Dubost C. Biological factors affecting long-term results of valvular heterografts. J. Thorac. Cardiovasc. Surg. 1969;58(4):467–483. PMID: 5344189.

27. Bourguignon T., Bouquiaux-Stablo A.L., Loardi C., Mirza A., Candolfi P., Marchand M. et al. Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J. Thorac. Cardiovasc. Surg. 2014;148(5):2004–2011.e1. https://doi.org/10.1016/j.jtcvs.2014.02.050

28. Bourguignon T., El Khoury R., Candolfi P., Loardi C., Mirza A., Boulanger-Lothion J. et al. Very long-term outcomes of the Perimount aortic valve in patients aged 60 or younger. Ann. Thorac. Surg. 2015;100:853–859. https://doi.org/10.1016/j.athoracsur.2015.03.105

29. Barbarash L.S., Zhuravleva I.Yu. Evolution of bioprosthetic heart valves: achievements and problems of two decades. Complex issues of cardiovascular diseases. 2012;(1):4–11. (In Russ.). https://doi.org/10.17802/2306-1278-2012-1-4-11

30. Freitas-Ferraz A., Tirado-Conte G., Dagenais F., Ruel M., Al-Atassi T., Dumont E. et al. Aortic stenosis and small aortic annulus clinical challenges and current therapeutic alternatives. Circulation. 2019;139:2685– 2702. https://doi.org/10.1161/circulationaha.118.038408

31. Hannah E., Reis K.L. Current status of porcine heterograft prostheses. Circulation. 1976; 53/54(Suppl_3):27. PMID: 1033047.

32. Platt M.R., Mills L.J., Estrera A.S., Hillis L.D., Buja L.M., Willerson J.T. Marked thrombosis and calcification of porcine heterograft valves. Circulation. 1980;62(4):862–869. https://doi.org/10.1161/01.cir.62.4.862

33. Magilligan D.J. Jr., Lewin J.W. Jr., Jara F.M., Lee M.W., Alam M., Riddle J.M. et al: Spontaneous degeneration of porcine bioprosthetic valves. Ann. Thorac. Surg. 1980;30:259. https://doi.org/10.1016/s00034975(10)61254-4

34. Oyer P.E., Miller D.C., Stinson E.B., Reitz B.A., Moreno-Cabral R.J., Shumway N.E. Clinical durability of the Hancock porcine bioprosthetic valve. J. Thorac. Cardiovasc. Surg. 1980;80:824. https://doi.org/10.1016/S0022-5223(19)37688-3

35. Carpentier A., Deloche A., Relland J., Fabiani J.N., Forman J., Camilleri J.P. Six-year follow-up of glutaraldehyde-preserved heterografts. J. Thorac. Cardiovasc. Surg. 1974;68(5):771–782. PMID: 4214526.

36. Imamura E., Wada J. Open aortic bioprosthesis at zero pressure. A new concept in glutaraldehyde fixation of tissue valve. J. Cardiovasc. Surg. (Torino). 1980;21(5):617–624. PMID: 7451570.

37. Rossiter S.J., Miller D.C., Stinson E.R., Oyer P.E., Reitz B.A., Moreno-Cabral R.J. Hemodynamic and clinical comparison of the Hancock modified orifice and standard orifice bioprostheses in the aortic position. J. Thorac. Cardiovasc. Surg. 1980;80(1):54–60. PMID: 7382536.

38. Ionescu M.I., Tandon A.P., Maury D.A., Abid A. Heart valve replacement with the lonescu-Shiley pericardial xenograft. J. Thorac. Cardiovasc. Surg. 1977;73(1):31–42. PMID: 831009.

39. Brown J.M., O’Brien S.M., Wu C., Sikora J.A., Griffith B.P., Gammie J.S. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J. Thorac. Cardiovasc. Surg. 2009;137(1):82–90. https://doi.org/10.1016/j.jtcvs.2008.08.015

40. Ionescu M.I. In The Beginning... Conception, Construction and Clinical Use of the First Pericardial Valve. In: The pericardial heart valve. The Odyssey of a Continuously Evolving Concept, 1971–2014. London: Society for Cardiothoracic Surgery in Great Britain and Ireland; 2014:1–35. URL: https://www.ctsnet.org/sites/default/files/images/Pericardial%20web%20res%20final.pdf (04.04.2025).

41. Jamieson W.R.E., Germann E., Aupart M.R. Neville P.H., Marchand M.A., Fradet G.J. 15-year comparison of CE Supra-Annular porcine and PERIMOUNT aortic bioprostheses. Asian Cardiovasc. Thorac. Ann. 2006;14(3):200–205. https://doi.org/10.1177/021849230601400306.

42. Kumar T., Singh A., Thakre S., Acharya S., Shukla S., Kumar S. Scientific evolution of artificial heart valves: a narrative review. Cureus. 2023;15(7):e42131. https://doi.org/10.7759/cureus.42131

43. Cooper D.K. How important is the anti-Gal antibody response following the implantation of a porcine bioprosthesis? J. Heart Valve Dis. 2009;18(6):671–672. PMID: 20099716.

44. Manji R.A., Menkis A.H., Ekser B., Cooper D.K. The future of bioprosthetic heart valves. Indian J. Med. Res. 2012;135(2):150–151. PMID: 22446853.

45. Klautz R.J.M., Kappetein A.P., Lange R., Dagenais F., Labrousse L., Bapat V. et al. Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis. Eur. J. Cardiothorac. Surg. 2017;52(3):425–431. https://doi.org/10.1093/ejcts/ezx066

46. Bavaria J.E., Griffith B., Heimansohn D.A., Rozanski J., Johnston D.R., Bartus K. et al. COMMENCE Trial Investigators. Five-year outcomes of the COMMENCE trial investigating aortic valve replacement with RESILIA tissue. Ann. Thorac. Surg. 2023;115(6):1429–1436. https://doi.org/10.1016/j.athoracsur.2021.12.058

47. Jabbour R.J., Mikhail G.W. Valve durability – is this the Achilles’ heel of TAVI? EuroIntervention. 2019;14(15):e1544–e1547. https://doi.org/10.4244/EIJV14I15A263

48. Ler A., Ying Y.J., Sazzad F., Choong A.M.T.L., Kofidis T. Structural durability of early-generation Transcatheter aortic valve replacement valves compared with surgical aortic valve replacement valves in heart valve surgery: a systematic review and meta-analysis. J. Cardiothorac. Surg. 2020;15(1):127. https://doi.org/10.1186/s13019-020-01170-7

49. Ovcharenko E.A., Klyshnikov K.Y., Glushkova T.V., Nyshtaev D.V., Kudryavtseva Yu.A., Savrasov G.V. Xenopericardial graft selection for valve apparatus of transcatheter heart valve bioprosthesis Biomedical Engineering. 2016;49(5):253–257. https://doi.org/10.1007/s10527-016-9543-0